Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers

British Journal of Cancer

Volumn 88, Issue 4, 2003, Pages 530-536

  Shono, Y ^a   Tanimura, H ^a   Iwahashi, M ^a   Tsunoda, T ^a   Tani, M ^a   Tanaka, H ^a   Matsuda, K ^a   Yamaue, H ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colon cancer; Mutant p21; Pancreatic cancer; Peptide vaccination; T cells

Indexed keywords

GAMMA INTERFERON; HLA DQ ANTIGEN; HLA DR ANTIGEN; RAS PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; T LYMPHOCYTE;

CELL DIVISION; COLORECTAL NEOPLASMS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; T-LYMPHOCYTES;

EID: 0037463282     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600697     Document Type: Article

References (31)

1. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinoma of the exocrine pancreas contain mutant c-Ki-ras genes. Cell 53: 549-554.
2. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689
3. Bos JL, Fearon ER, Hamilton SR, Verlaan de Vries M, van Boom JH, van der Eb AJ, Vogelstein B (1987) Prevalence of ras gene mutation in human colorectal cancer. Nature (Lond.) 327: 293-297
4. Cheever MA, Disis ML, Bernhard H, Chen W, Gralow JR, Hand SL, Huseby ES, Qin HL (1995) Immunity to oncogenic proteins. Irnmunol Rev 145: 33-59
5. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumourigenesis. Cell 61: 759-767
6. Fossum B, Breivik J, Meling GI, Gedde-Dahl T, Gaudernack G (1994a) A Ki-ras 13GLY→ASP mutation is recognised by HLA-DQ7 restricted T-cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? Int J Cancer 58: 506-511
7. Fossum B, Gedde-Dahl III T, Breivik J, Eriksen JA, Gaudernack G (1994b) p21-ras-peptide-specific T-cell responses in-patients with colorectal cancer. CD4+ and CD8+ T-cells recognised a peptide corresponding to a common mutation (13Gly→Asp). Int J Cancer 56: 40-45
8. Fossum B, Gedde-Dahl T, Hansen T, Eriksen JA, Thorsby E, Gaudernack G. (1993) Overlapping epitopes encompassing a point mutation (12Gly→Arg) in p21 ras can be recognised by HLA-DR, -DP and -DQ restricted T-cells. Eur J Immunol 23: 2687-2689
9. Fossum B, Oslen AC, Thorsby E, Gaudernack G (1995) CD8+ T-cells from a patient with colon carcinoma, specific for mutant p21 ras-derived peptide (GLY13
10. Gedde-Dahl III T, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G (1992) Memory T-cells of a patient with follicular thyroid carcinoma recognise peptides derived from mutated p21 ras (Gln→Leu61). Int Immnol 4: 1331-1337
11. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F (1994) Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 180: 2353-2358
12. Harmer PJ, La Vecchio J, Ng S, Delellis R, Wolfe H, Carney WP (1991) Activated Val-12 ras p21 in cell culture fluids and mouse plasma. Oncogene 6: 1609-1615
13. Jung S, Schluesener HJ (1991) Human T lymphocytes recognise a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173: 273-276
14. Juretic A, Jurgens-Gobel J, Schaefer C, Noppen C, Willimann TE, Kocher T, Zuber M, Harder F, Heberer M, Spagnoli GC (1996) Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: an analysis of specific T-cell-receptor gene usage. Int J Cancer 68: 471-478
15. Kawakami Y, Rosenberg SA (1997) Human tumour antigen recognised by T-cells. Immunol Res 16: 313-339
16. Marx J (1989) Many gene changes found in cancer. Science 246: 1386-1388
17. Nakagawa T, Saitoh S, Imoto S, Itoh M, Tsutsumi M, Hikiji K, Nakao Y, Fujita T (1991) Loss of multiple point mutations of ras genes associated with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. Br J Haematol 77: 250-252
18. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumour lysate-pulsed dendritic cells. Nat Med 4: 328-332
19. Peace DJ, Chen W, Nelson H, Cheever MA (1991a) T-cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol 146: 2059-2065
20. Peace DJ, Smith JW, Chen W, You SG, Cosand WL, Blake J, Cheever MA (1991b) Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J Exp Med 179: 473-479
21. Qin H, Chen W, Takahashi M, Disis ML, Byrd DR, McCahill L, Bertram KA, Fenton RG, Peace DJ, Cheever MA, Parkfurst MR, Kawahami Y, Seipp CA, Einhorn JH, White DE (1995) CD4+ T-cell immunity to ras protein in pancreatic and colon cancer patients. Cancer Res 55: 2984-2987
22. Rammensee HG (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 7: 85-96
23. Rosenberg SA, Yang JC, Schwarzentruber DJ et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327
24. Rudensky AY, Preston-Hurburt P, Jneway Jr CA (1991) Sequence analysis of peptides bound to MHC class II molecules. Nature 353: 622
25. Suwa H, Yoshimura T, Yamaguchi N, Kanehira K, Manabe T, Imamura M, Hiai H, Fukumoto M (1994) Ki-ras and p53 alteration in genomic DNA and transcripts of human pancreatic adenocarcinoma cell. Jpn J Cancer Res 85: 1005-1014
26. Takahashi M, Chen W, Byrd DR, Disis ML, Husby ES, Qin H, Cheerer MA (1995) Antibody to ras protein in colon cancer. Clini Cancer Res 1: 1071-1077
27. Takeda S, Ichii S, Nakamura Y (1993) Detection of Ki-ras mutation in sputum by mutant-allele-specific-amplification (MASA). Human Muta 2: 112-117
28. Tsang KY, Nieroda CA, Defilippi R, Chung YK, Yamaue H, Schlom J (1994) Induction of human cytotoxic T-cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res 3: 183-193
29. Valenzuela DM, Groffen J (1986) Four human carcinoma cell lines with novel mutation in of c-Ki-ras oncogene. Nucleic Acids Res 14: 843-852
30. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647
31. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumour development. N Engl J Med 319: 525-531